Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
By Chris Crowder, executive vice president, GovCon, Unanet Across government contracting, many leaders feel good about their pipelines. Opportunity volume looks strong.…
Sabel Systems Technology Solutions has appointed Stephen Vukovich, an IT implementation project manager, as interim senior vice president and president…
Defensive cyber has become foundational to federal digital modernization strategy, shaping how agencies approach cloud adoption, AI integration and enterprise…
